REG - Syncona Limited - Notice of Results

SynconaAnnouncement

19/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220519:nRSS0096Ma&default-theme=true

RNS Number : 0096M  Syncona Limited  19 May 2022

 

 

Syncona Limited

 

Notice of Final Results

 

19 May 2022

 

Syncona Ltd, a leading healthcare company focused on founding, building and
funding a portfolio of global leaders in life science, will announce its final
results for the year ended 31 March 2022 on Thursday 16 June 2022.

 

Syncona will host a webcast and conference call the same day at 9.00am BST,
with an opportunity to ask questions via the conference call line. The webcast
will be available on the Company's website at https://www.synconaltd.com/
(https://www.synconaltd.com/) or via this
(https://www.lsegissuerservices.com/spark/SynconaLtd/events/8bc7c7e7-571b-43f9-aa48-0826225c1403)
link. Alternatively, please contact Syncona@fticonsulting.com
(mailto:Syncona@fticonsulting.com) for details of the conference call.

 

 ENDS 

 

Enquiries

 

Syncona Ltd

 

Natalie Garland-Collins / Fergus Witt

Tel: +44 (0) 7714 916615

 

FTI Consulting

 

Ben Atwell / Julia Bradshaw / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

About Syncona

 

Syncona's purpose is to invest to extend and enhance human life. We do this by
founding and building companies to deliver transformational treatments to
patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science
to create a diversified portfolio of 15-20 globally leading healthcare
businesses for the benefit of all our stakeholders. We focus on developing
treatments for patients by working in close partnership with world-class
academic founders and management teams. Our balance sheet underpins our
strategy enabling us to take a long-term view as we look to improve the lives
of patients with no or poor treatment options, build sustainable life science
companies and deliver strong risk-adjusted returns to shareholders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBKFBBABKDKPD